Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis is a long-lasting lung disease that causes scarring (fibrosis) in the tissue between the air sacs of the lungs. The scarring starts in the outer and lower parts of the lungs and slowly spreads. The scar tissue makes the lungs stiff. Stiff lungs cannot fill with air fully. This lowers oxygen in the blood. Doctors do not know the exact cause. The disease has a special microscopic and CT pattern called usual interstitial pneumonia (UIP). IPF usually affects adults over 50. It often gets worse over time, with periods of stable breathing and sudden flares.

Idiopathic pulmonary fibrosis (IPF) is a long-lasting lung disease where the delicate air sacs and supporting tissue of the lungs (the interstitium) thicken and scar for reasons we do not fully know. “Idiopathic” means the cause is unknown. “Fibrosis” means scarring. Over time, the scarring makes the lungs stiff. Stiff lungs do not expand well, so it becomes hard to breathe in enough air. Oxygen then has trouble moving from the lungs into the blood. People usually notice slowly increasing breathlessness with activity and a dry, hacking cough. Doctors hear “Velcro-like” crackles with a stethoscope. Clubbing (widening) of the fingertips may appear. IPF mostly affects adults over 60 and is more common in people assigned male at birth and in former smokers. The condition tends to worsen over years, but the speed of worsening can vary. Some people remain stable for a while; others have sudden “acute exacerbations,” where symptoms rapidly get worse. There is no known cure, but medicines, oxygen, pulmonary rehabilitation, careful infection prevention, and in selected people lung transplantation can slow the disease and improve day-to-day life.

Other Names

• Idiopathic interstitial pneumonia—UIP pattern

• Cryptogenic fibrosing alveolitis (older term, especially used in the UK)

• Primary pulmonary fibrosis (older term)

• Sporadic or familial pulmonary fibrosis (when it runs in families)

Idiopathic pulmonary fibrosis is a chronic lung disease with unknown cause. The lung’s thin lining between air sacs becomes injured. Healing is abnormal. Fibroblasts lay down collagen and make scar tissue. The lungs become stiff, small, and honeycombed on high-resolution CT. People develop dry cough, breathlessness that first appears with exercise, low oxygen, and clubbing of the fingers. The disease often progresses over years, and sudden acute worsening can occur. Two antifibrotic drugs (pirfenidone and nintedanib) can slow decline but do not cure. Supportive oxygen, rehab, and, in selected patients, lung transplant improve survival and life quality.

---

How IPF Damages the Lung

The lung has millions of tiny air sacs called alveoli. A thin wall lets oxygen move into blood and carbon dioxide move out. In IPF, the covering cells on this wall get injured many times. Instead of normal healing, the body sends many fibroblasts. They make collagen and other fibers. These fibers thicken the wall and destroy the normal shape. Air sacs collapse and form “honeycomb” cysts. Small airways get pulled open (traction bronchiectasis). The lung becomes stiff, so breathing takes more effort. Oxygen falls, especially during activity. Over time, the right side of the heart can strain due to high pressure in lung vessels (pulmonary hypertension).

---

Types and Clinical Patterns

1. By imaging/histology (most used):

• Typical UIP: Subpleural, basal-predominant reticulation, honeycombing, traction bronchiectasis on HRCT; UIP on biopsy if done.

• Probable UIP: Similar but with fewer classic signs; biopsy may confirm.

• Indeterminate for UIP: Some fibrosis without clear pattern; further work-up needed.

• Alternative diagnosis suggested: Features point to another disease (e.g., hypersensitivity pneumonitis).

2. By origin:

• Sporadic IPF: No affected relatives.

• Familial pulmonary fibrosis (FPF): Two or more affected relatives; often linked to telomere or surfactant gene variants.

3. By speed of change (clinical phenotype):

• Slowly progressive: Gradual fall in lung function over years.

• Rapid progressor: Faster drop in forced vital capacity (FVC) and diffusion (DLCO).

• Acute exacerbation of IPF (AE-IPF): Sudden, severe worsening over days to weeks with new lung infiltrates.

4. By associated features:

• IPF with pulmonary hypertension: Coexisting high pressure in lung arteries.

• Combined pulmonary fibrosis and emphysema (CPFE): Emphysema in upper lobes and fibrosis in lower lobes.

• IPF with frequent reflux/aspiration: Prominent gastroesophageal reflux.

Types and clinical forms

1. Sporadic IPF. The most common form. It occurs in a person with no known family history.

2. Familial IPF. The same scarring pattern appears in two or more close relatives. In many, a gene related to mucus handling or telomere maintenance is involved.

3. Radiologic categories linked to UIP. Chest CT may show definite UIP, probable UIP, or indeterminate for UIP. These categories help decide if a biopsy is needed.

4. Rapid vs. slow progressors. Some people lose lung function quickly over months; others decline more slowly over years.

5. IPF with acute exacerbation. A sudden, unexplained worsening with new widespread lung inflammation on CT, often requiring hospital care.

6. IPF with pulmonary hypertension. Long-standing scarring can raise pressure in the lung arteries; this adds fatigue, swelling, and dizziness.

7. IPF with emphysema (CPFE overlap). Some people, usually current or former smokers, have both upper-lobe emphysema and lower-lobe fibrosis. Oxygen levels may drop sharply with exercise.

8. Early vs. advanced stage. Early disease may show mild breathlessness and subtle CT changes; advanced disease shows severe restriction, honeycombing, and oxygen need.

---

Causes and risk factors

IPF has no single proven cause. The items below are well-described risk factors and biological drivers that likely work together.

1. Aging of lung cells. Older alveolar cells repair poorly after minor injuries. This favors scarring rather than normal healing.

2. MUC5B promoter variant. A common genetic change near the MUC5B gene increases risk by altering mucus clearance in small airways.

3. Short telomeres and telomere gene mutations. Variants in TERT, TERC, RTEL1, PARN, and related genes shorten telomeres, limit cell renewal, and promote fibrosis.

4. Surfactant protein gene variants. Changes in SFTPC or SFTPA2 can make the lining cells of the air sacs more fragile.

5. Male sex and post-menopausal status. IPF is more common in men and after mid-life, suggesting hormonal and exposure differences.

6. Cigarette smoking. Smoke repeatedly injures the airway lining and increases oxidative stress, making scars more likely.

7. Metal dust exposure. Work exposures (e.g., steel, brass, welding) can irritate lung tissue over many years.

8. Wood and mineral dust exposure. Sawdust, stone cutting, and silica dust are linked with higher risk.

9. Ambient air pollution. Fine particles and ozone add to day-to-day epithelial injury.

10. Chronic micro-aspiration from reflux (GERD). Tiny drops of stomach acid reaching the lungs may trigger ongoing injury and cough.

11. Viral triggers. Prior or recurrent herpes family viruses (like EBV) and others may nudge the lung toward scarring after insults.

12. Bacterial community shifts in airways. Changes in the lower airway microbiome can sustain inflammation and fibrosis signals.

13. Oxidative stress. Imbalance between oxidants and antioxidants damages proteins, DNA, and membranes, encouraging fibrotic repair.

14. Abnormal TGF-β signaling. This key wound-healing pathway becomes overactive, pushing fibroblasts to lay down excess collagen.

15. Epithelial-mesenchymal transition (EMT). Injured lining cells may convert toward a scar-forming state, increasing matrix deposition.

16. Repeated micro-injury from infections or pollutants. Small hits, each too minor to notice, add up over time.

17. Family history of pulmonary fibrosis. Even without a known mutation, family clustering increases risk.

18. Metabolic factors (e.g., diabetes). Metabolic stress and glycation may worsen repair quality and fuel fibrosis.

19. Sleep-disordered breathing and intermittent hypoxia. Nighttime oxygen dips may drive vascular stress and scarring pathways.

20. Prior lung injury or surgery. A major lung insult can tip healing toward fibrosis in susceptible people.

---

Symptoms

1. Breathlessness with activity. You first notice shortness of breath when climbing stairs, walking uphill, or carrying loads.

2. Breathlessness at rest (later). As scarring advances, even quiet breathing can feel hard.

3. Persistent dry cough. The cough is often hacking and unproductive, worse with talking or exertion.

4. Fatigue. Low oxygen and extra breathing effort make you feel worn out.

5. Reduced exercise tolerance. Distances shrink on walks; tasks need more breaks.

6. Chest tightness or discomfort. Stiff lungs can feel tight, though chest pain is not a common feature.

7. Unintentional weight loss. Burning more energy to breathe and reduced appetite can lead to weight loss.

8. Sleep trouble. Cough or breathlessness can wake you; some need extra pillows or oxygen at night.

9. Morning headaches. Low oxygen at night can cause dull headaches on waking.

10. Hoarseness. Constant coughing or reflux irritation can strain the voice.

11. Heart-racing or palpitations with effort. The heart works harder to supply oxygen-poor tissues.

12. Anxiety and low mood. Breathlessness and uncertainty are stressful and affect mood.

13. Dizziness on exertion. If pulmonary hypertension develops, blood pressure may drop with activity.

14. Swollen ankles (later). Right-sided heart strain from lung disease can cause leg swelling.

15. Frequent chest infections. Stiff, scarred lungs clear mucus less well, which may invite infections.

---

Diagnostic tests

Physical examination

1. Listening for “Velcro” crackles. A doctor hears fine, dry crackles at the lung bases, like pulling apart Velcro. This reflects tiny airways popping open in stiff, scarred areas.

2. Checking for digital clubbing. The fingertips may look bulbous with curved nails. Clubbing suggests long-standing low oxygen and chronic lung disease.

3. Looking for cyanosis and low oxygen signs. Blue lips or fingertips and rapid breathing point to poor oxygen transfer.

4. Assessing chest wall movement. The chest may expand less than normal, especially at the bases, because the lungs are stiff.

5. Searching for signs of pulmonary hypertension and right-heart strain. A loud second heart sound, neck vein distension, leg swelling, or liver tenderness can signal advanced disease.

Manual or bedside functional tests

6. Six-Minute Walk Test (6MWT). You walk on a flat hallway for six minutes. Clinicians record distance and oxygen drop. Falling oxygen and shorter distance track disease severity and response to therapy.

7. One-Minute Sit-to-Stand test. You stand up and sit down repeatedly for one minute. The number of repetitions and any oxygen drop show functional reserve without needing a long hallway.

8. Stair-climb test. Climbing a set number of steps gauges breathlessness and oxygen stability during a realistic daily task.

9. Chest expansion measurement with a tape. A simple tape around the chest checks how much the chest expands with deep breathing; low expansion supports restriction.

10. Peak cough flow or simple peak flow check. A handheld meter gives a quick view of expiratory effort. Although designed for airway disease, very low values with normal airways can reflect global respiratory weakness and low reserve.

Laboratory and pathological tests

11. Spirometry (forced vital capacity, FVC). FVC is typically reduced, showing restriction. This number is a key marker followed over time.

12. Diffusing capacity for carbon monoxide (DLCO). DLCO falls early and often more than FVC, showing poor oxygen transfer across the scarred membrane.

13. Arterial blood gas (ABG). A small artery sample measures oxygen, carbon dioxide, and acidity. IPF often shows low oxygen and an increased A–a gradient, especially with exercise.

14. Autoimmune serology panel. Tests like ANA, RF, anti-CCP, ENA, and myositis antibodies help rule out connective tissue-related interstitial lung disease that can mimic IPF.

15. Lung tissue diagnosis (surgical biopsy or transbronchial cryobiopsy) when needed. Pathology shows the UIP pattern: patchy fibrosis, architectural distortion, honeycombing, and fibroblastic foci, with scarring worse at the bases and edges.

Electrodiagnostic and monitored physiology

16. Pulse oximetry at rest and with exertion. A finger sensor tracks oxygen saturation continuously during clinic and during walking tests. Drop with activity is common in IPF.

17. Cardiopulmonary exercise testing (CPET) with ECG and breath-by-breath gas analysis. This supervised test measures peak oxygen use, ventilation, heart rhythm, and gas exchange limits. It helps separate lung, heart, and deconditioning causes of breathlessness.

Imaging tests

18. Chest X-ray. It is quick and shows reticular (net-like) patterns and small lung volumes, mostly at the bases. It is not enough to diagnose IPF but can suggest fibrosis.

19. High-resolution CT (HRCT) of the chest. HRCT is central. A definite UIP pattern shows basal and subpleural reticulation, traction bronchiectasis, and honeycombing, with little ground-glass and no features pointing to another disease. When HRCT is “probable UIP,” a tissue sample may be considered.

20. Transthoracic echocardiogram. Heart ultrasound estimates lung artery pressures and right-heart strain. It tracks the important complication of pulmonary hypertension in advanced IPF.

Non-pharmacological treatments

Physiotherapy & Pulmonary Rehabilitation

1. Supervised pulmonary rehabilitation (core program)
   Pulmonary rehab is an 8–12+ week, team-based program that blends exercise training, breathing practice, education, and support. Purpose: build endurance, reduce breathlessness, and teach self-management. Mechanism: repeated, tailored aerobic and strength work improves heart-muscle efficiency, trains breathing muscles, and reduces the sensation of dyspnea for a given workload. Education reduces anxiety and teaches pacing, rescue plans, and oxygen use. Benefits: better walking distance (e.g., 6-minute walk), improved quality of life, less anxiety about exertion, and safer activity at home.

2. Interval walking with pacing and rests
   This is structured walk training with planned slow-downs and “micro-rests.” Purpose: extend activity time without triggering severe breathlessness. Mechanism: keeping exertion in the “talk test” zone limits lactic acid buildup and reduces ventilatory demand. Benefits: people can do more daily tasks, feel more in control, and recover faster after activity.

3. Inspiratory muscle training (IMT)
   Using a handheld device that adds resistance to inhaling. Purpose: strengthen the diaphragm and accessory muscles. Mechanism: progressive resistance stimulates muscle adaptation just like weight training. Benefits: lower breathlessness on exertion, improved inspiratory pressures, and sometimes better cough effectiveness.

4. Active cycle of breathing technique (ACBT)
   A sequence of relaxed breathing, deep breaths, and huffs. Purpose: mobilize secretions when infections or mucus complicate IPF. Mechanism: controlled airflow shifts mucus from small to larger airways. Benefits: easier clearance, fewer coughing fits, and less fatigue from coughing.

5. Diaphragmatic (belly) breathing
   Slow nasal inhalation with abdominal rise, long exhalation through pursed lips. Purpose: reduce dynamic hyperinflation and anxiety. Mechanism: optimizes diaphragm use, slows respiratory rate, and improves gas mixing. Benefits: calmer breathing, lower perceived dyspnea, and better tolerance of activity.

6. Pursed-lip breathing during exertion
   Inhale through the nose, exhale through nearly closed lips. Purpose: prolong exhalation and maintain airway pressure. Mechanism: creates a small back-pressure that keeps small airways open longer. Benefits: smoother breathing pattern and reduced “air hunger.”

7. Upper- and lower-body resistance training
   Light dumbbells, bands, or body-weight exercises 2–3 times a week. Purpose: preserve muscle mass and functional strength. Mechanism: resistance work increases motor unit recruitment and counters steroid/myopathy risks. Benefits: stronger legs and arms for stairs, transfers, and chores; less fatigue.

8. Balance and fall-prevention drills
   Heel-to-toe walking, single-leg stands, and safety practice. Purpose: prevent injury in deconditioned adults using oxygen tubing or feeling dizzy. Mechanism: improves proprioception and core stability. Benefits: fewer falls, greater confidence moving around the home.

9. Energy-conservation training
   Task simplification, sitting for chores, organizing tools within reach. Purpose: reduce daily energy drain. Mechanism: pacing and ergonomic changes lower oxygen demand over the day. Benefits: more stamina left for meaningful activities.

10. Posture optimization and chest mobility
    Gentle thoracic stretches and postural cues. Purpose: counter rounded shoulders and chest stiffness. Mechanism: lengthening anterior chest wall and mobilizing ribs improves inspiratory excursion. Benefits: slightly easier breaths and less upper-back ache.

11. Airway clearance adjuncts (when mucus present)
    Oscillating PEP devices or gentle autogenic drainage. Purpose: help remove secretions during infections. Mechanism: oscillations reduce mucus viscosity; controlled airflow shifts secretions proximally. Benefits: fewer prolonged coughing spells and better sleep.

12. Cough control and hydration strategy
    Sip water, swallow, and use “huff” instead of repetitive hard coughs. Purpose: reduce cough irritation cycles. Mechanism: moist mucosa and gentler flows lower laryngeal stimulation. Benefits: less throat pain and fewer cough-induced desaturations.

13. Home pulse-oximeter guided activity
    Using SpO₂ feedback to tailor pace and oxygen flow per clinician plan. Purpose: keep saturations in target range during tasks. Mechanism: real-time biofeedback. Benefits: safer exercise, fewer dizzy episodes, and better confidence.

14. Heat-moisture exchange (HME) mask in cold/dry air
    A simple mask that warms and moistens inhaled air. Purpose: reduce cold-air cough and breathlessness. Mechanism: protects airway receptors from dry, cold flow. Benefits: more comfortable outdoor walking in winter.

15. Pulmonary rehab maintenance (booster sessions)
    Monthly or quarterly check-ins after the core program. Purpose: prevent deconditioning. Mechanism: accountability plus tune-ups of home plan. Benefits: sustained gains and earlier detection of decline.

Mind-Body, Education, and Practical Supports

16. Breathing-focused mindfulness and relaxation
    Short, guided sessions that pair slow breathing with body scan. Purpose: lower anxiety that worsens dyspnea perception. Mechanism: reduces sympathetic arousal and cortical attention to breath cues. Benefits: calmer breathing, better sleep, less panic during flares.

17. Cognitive behavioral therapy (CBT) for breathlessness
    Brief, structured therapy to reframe fear-avoidance patterns. Purpose: break the cycle of “I can’t move or I’ll suffocate.” Mechanism: graded exposure and cognitive reframing. Benefits: more activity, less distress, and improved quality of life.

18. Sleep optimization coaching
    Regular schedule, head-of-bed elevation, screen hygiene, and evaluation for sleep apnea. Purpose: improve restorative sleep and daytime energy. Mechanism: better sleep architecture and oxygenation at night. Benefits: less daytime fatigue, more rehab capacity.

19. Vaccination and infection-prevention education
    Influenza, COVID-19, pneumococcal, RSV where appropriate; hand hygiene; sick-day plans. Purpose: reduce infections that accelerate decline. Mechanism: immune priming and exposure reduction. Benefits: fewer exacerbations and hospital stays.

20. Environmental/occupational exposure reduction
    Avoid wood/metal dust, molds, fumes; use masks/ventilation. Purpose: minimize further lung injury. Mechanism: lower inhaled irritants that can provoke inflammation. Benefits: fewer symptom flares and slower decline.

21. Nutritional counseling for high-protein, anti-inflammatory pattern
    Adequate protein, fruits/vegetables, whole grains; manage reflux. Purpose: maintain muscle and support immune health. Mechanism: sufficient amino acids and micronutrients; reflux control limits micro-aspiration. Benefits: better strength, fewer infection risks.

22. GERD management education
    Meal timing, bed elevation, weight management, avoiding trigger foods. Purpose: reduce silent reflux and micro-aspiration. Mechanism: mechanical and behavioral reflux barriers. Benefits: fewer nocturnal cough episodes and potential protection against exacerbations.

23. Oxygen safety and travel planning
    Tubing safety, fire safety, airline rules, portable concentrator use. Purpose: keep life active and safe with oxygen. Mechanism: planning removes barriers to trips and family events. Benefits: sustained social participation and mood.

24. Advance care planning and symptom action plans
    Early talks about goals, do-not-resuscitate preferences, and flare steps. Purpose: align care with values and reduce crisis uncertainty. Mechanism: shared decision-making. Benefits: greater control and less stress for patients and families.

25. Peer support groups (in-person or virtual)
    Connecting with others who live with IPF. Purpose: reduce isolation and share practical tips. Mechanism: social learning and emotional validation. Benefits: improved coping, adherence, and hope.

---

Drug treatments

(Only two medicines are proven to slow IPF: nintedanib and pirfenidone. Others below treat symptoms or complications. Doses are typical ranges—your clinician will individualize. Do not start/stop medicines without medical guidance.)

1. Nintedanib
   Class: Tyrosine kinase inhibitor (targets VEGF, FGF, PDGF receptors).
   Typical dose/time: 150 mg by mouth twice daily with food; dose reductions or 100 mg BID if needed.
   Purpose: slow the rate of lung function decline (FVC loss).
   Mechanism: dampens fibroblast activation and proliferation that drives scarring.
   Side effects: diarrhea, nausea, liver enzyme elevations, decreased appetite; rare bleeding risk. Regular liver tests and diarrhea management (loperamide, hydration) are important.

2. Pirfenidone
   Class: Antifibrotic/anti-inflammatory.
   Typical dose/time: titrated to 801 mg three times daily with food (total 2403 mg/day).
   Purpose: slow FVC decline and disease progression.
   Mechanism: reduces profibrotic cytokines (e.g., TGF-β) and collagen deposition.
   Side effects: nausea, dyspepsia, photosensitivity rash, fatigue; liver enzyme elevations. Use sun protection; monitor labs.

3. Antidiarrheals for nintedanib-related diarrhea (e.g., loperamide)
   Class: Peripheral opioid receptor agonist.
   Dose/time: per label as needed at first loose stool, then as directed.
   Purpose: improve tolerability so antifibrotic therapy can continue.
   Mechanism: slows gut transit.
   Side effects: constipation, cramps if overused.

4. Antiemetics/acid suppression for dyspepsia (e.g., ondansetron; PPIs/H2 blockers when appropriate)
   Class: 5-HT3 antagonist; proton pump inhibitor; H2 blocker.
   Dose/time: individualized.
   Purpose: control nausea/reflux that worsens cough and adherence.
   Mechanism: central antiemetic action; reduced gastric acid production.
   Side effects: constipation/headache (ondansetron); PPIs may cause diarrhea, low magnesium/B12 with long-term use—use only when indicated.

5. Cough suppressants (dextromethorphan or benzonatate)
   Class: Antitussives.
   Dose/time: as labeled for chronic dry cough.
   Purpose: reduce cough burden and improve sleep.
   Mechanism: central cough-center modulation (dextromethorphan); peripheral anesthetic effect (benzonatate).
   Side effects: dizziness, drowsiness; avoid exceeding doses.

6. Low-dose morphine for refractory dyspnea/cough (specialist-guided)
   Class: Opioid analgesic.
   Dose/time: very low oral doses under close supervision.
   Purpose: lessen the sensation of air hunger and severe cough.
   Mechanism: reduces central perception of dyspnea and cough drive.
   Side effects: constipation, sedation; safety planning essential.

7. Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD)
   Class: Prostacyclin analogue (inhaled).
   Dose/time: titrated inhalations four times daily.
   Purpose: improve exercise capacity in people with confirmed PH-ILD.
   Mechanism: pulmonary vasodilation and antiplatelet effects.
   Side effects: cough, throat irritation, headache; requires PH specialist evaluation.

8. Sildenafil in selected PH-IPF cases (specialist-selected)
   Class: PDE-5 inhibitor.
   Dose/time: typically 20 mg three times daily when indicated.
   Purpose: support right-heart function and exercise tolerance in carefully chosen patients.
   Mechanism: enhances nitric-oxide signaling → vasodilation.
   Side effects: headache, flushing, hypotension; avoid with nitrates.

9. Short courses of systemic corticosteroids for acute exacerbations
   Class: Glucocorticoid.
   Dose/time: high-dose regimens in hospital settings.
   Purpose: treat sudden, severe inflammatory flares.
   Mechanism: broad anti-inflammatory effects.
   Side effects: high blood sugar, mood changes, infection risk, muscle weakness; not for routine, long-term use in stable IPF.

10. Antibiotics for bacterial respiratory infections
    Class: Depends on organism (e.g., macrolides, β-lactams).
    Dose/time: per culture/clinical protocol.
    Purpose: treat infections that worsen gas exchange and trigger flares.
    Mechanism: pathogen eradication.
    Side effects: GI upset, drug-drug interactions; use only when infection is suspected/confirmed.

11. Antiviral therapy for influenza/COVID-19/RSV as indicated
    Class: Neuraminidase inhibitors, polymerase inhibitors, targeted antivirals.
    Dose/time: per guideline, earliest possible.
    Purpose: shorten illness, reduce complications.
    Mechanism: blocks viral replication. Side effects: vary by agent.

12. Diuretics when right-heart strain or fluid overload present
    Class: Loop or thiazide diuretics.
    Dose/time: titrated to symptoms and labs.
    Purpose: reduce leg swelling and breathlessness from fluid.
    Mechanism: increases salt/water excretion.
    Side effects: electrolyte shifts, dehydration; monitor closely.

13. Anxiolytics for panic-linked dyspnea (non-sedating options preferred)
    Class: SSRIs/SNRIs when anxiety disorder coexists; avoid routine sedatives in severe respiratory compromise.
    Purpose: reduce anxiety that amplifies breathlessness.
    Mechanism: central serotonin/norepinephrine modulation.
    Side effects: nausea, sleep changes; start low/go slow.

14. Antireflux therapy in clear, troublesome GERD
    Class: PPIs/H2 blockers, alginates.
    Purpose: reduce micro-aspiration risk and cough triggers.
    Mechanism: lowers acid volume and exposure.
    Side effects: see item 4; use only when clinically indicated.

15. Vaccines (preventive medicines)
    Class: Inactivated or recombinant vaccines (influenza, COVID-19, pneumococcal, RSV where eligible).
    Purpose: prevent infections that cause decompensation.
    Mechanism: immune memory against pathogens.
    Side effects: brief sore arm, fatigue; strong overall benefit.

---

Dietary molecular supplements

1. Omega-3 fatty acids (EPA/DHA)
   Dose: commonly 1–2 g/day combined EPA+DHA with meals.
   Function/mechanism: anti-inflammatory lipid mediators (resolvins/protectins) may dampen lung inflammation and support cardiovascular health for safer exercise. Note: evidence in IPF is indirect but biologically plausible.

2. Vitamin D (if deficient)
   Dose: individualized repletion, often 1000–2000 IU/day maintenance after correction.
   Mechanism: immune modulation and bone/muscle support, important if on intermittent steroids or deconditioned. Evidence: strong for deficiency correction; specific IPF outcomes uncertain.

3. N-acetylcysteine (NAC)
   Dose: 600–1200 mg/day oral in selected cases.
   Mechanism: antioxidant/glutathione precursor. Evidence: large trials did not show benefit as monotherapy in IPF; if used, it should be as an adjunct for oxidative stress under medical advice.

4. Curcumin (turmeric extract)
   Dose: often 500–1000 mg/day standardized curcuminoids with piperine for absorption.
   Mechanism: NF-κB/TGF-β pathway modulation (preclinical). Evidence: human IPF data limited; avoid with anticoagulants due to bleeding risk.

5. Quercetin
   Dose: 250–500 mg/day in divided doses.
   Mechanism: antioxidant and senolytic actions in preclinical fibrosis models. Evidence: early and indirect; discuss risks/benefits.

6. Coenzyme Q10 (ubiquinone)
   Dose: 100–200 mg/day with fat-containing meal.
   Mechanism: mitochondrial support and anti-oxidative effects; may help statin users or those with fatigue. Evidence: general; IPF-specific data minimal.

7. Magnesium (if low)
   Dose: 200–400 mg elemental/day, citrate or glycinate forms.
   Mechanism: muscle and nerve function; may reduce cramps from diuretics. Evidence: supportive for deficiency; not disease-modifying.

8. Probiotic yogurt or capsules
   Dose: per label daily.
   Mechanism: gut-lung axis and immune tone; may reduce antibiotic-associated diarrhea. Evidence: general; IPF-specific outcomes unknown.

9. Green-tea catechins (EGCG)
   Dose: 225–400 mg/day standardized extract.
   Mechanism: antifibrotic signaling in preclinical work. Evidence: limited human data; monitor for liver effects.

10. Protein supplements (whey/plant blends)
    Dose: 20–30 g protein after rehab sessions if dietary intake is low.
    Mechanism: supports muscle repair and preserves lean mass. Evidence: strong for sarcopenia prevention; indirect for IPF.

---

Immunity-booster / regenerative / stem-cell” drugs

1. Mesenchymal stromal cell (MSC)–based therapies (investigational)
   Dose: trial-defined. Function: potential anti-inflammatory and antifibrotic paracrine effects. Mechanism: secretion of cytokines/exosomes that may modulate fibroblast behavior. Status: research only; unknown long-term safety/efficacy.

2. Zinpentraxin alfa (recombinant human pentraxin-2, investigational)
   Function: aims to shift monocytes/macrophages away from profibrotic phenotypes. Mechanism: innate immune modulation. Status: mixed/ongoing research; not approved for IPF.

3. Pamrevlumab (anti-CTGF monoclonal antibody, investigational)
   Function: blocks connective-tissue growth factor implicated in fibrosis. Mechanism: antifibrotic pathway inhibition. Status: phase-3 results have been disappointing in some studies; not approved.

4. Autotaxin/LPA pathway inhibitors (investigational)
   Function: reduce lysophosphatidic acid signaling linked to fibrosis. Mechanism: antifibrotic signaling blockade. Status: prior candidates failed; research continues.

5. PDE4B-selective inhibitors (e.g., BI 1015550, investigational)
   Function: anti-inflammatory/antifibrotic effects with better GI tolerability than non-selective PDE4. Mechanism: increases cAMP in key cells. Status: under study; not standard of care.

6. Gene-targeted approaches (TOLLIP, telomere biology—clinical-trial context only)
   Function: tailor therapies to certain molecular endotypes. Mechanism: pathway-specific modulation. Status: research stage; not for routine clinical use.

---

Surgeries and procedures

1. Lung transplantation (single or double)
   Procedure: surgical replacement of one or both lungs at specialized centers. Why: the only intervention that can replace scarred lungs when disease is advanced and other options are exhausted. Notes: strict selection, lifelong anti-rejection therapy, and infection vigilance are required.

2. Anti-reflux surgery (laparoscopic fundoplication) in carefully selected patients
   Procedure: a wrap around the lower esophagus to reduce reflux. Why: may reduce micro-aspiration in patients with severe, proven GERD not controlled by lifestyle/medications. Notes: potential benefits must be weighed against surgical risks; discuss in a multidisciplinary team.

3. Surgical management of recurrent pneumothorax (pleurodesis/bleb repair)
   Procedure: seal the pleural space to prevent repeat lung collapse. Why: fibrosis can predispose to secondary spontaneous pneumothorax in some cases. Notes: individualized decision based on lung reserve.

4. Tracheostomy for prolonged ventilation (rare and goal-of-care driven)
   Procedure: surgical airway for long-term ventilation support. Why: selected ICU scenarios during acute exacerbation when consistent with patient goals. Notes: not disease-modifying; significant burdens and careful planning required.

5. Surgical lung biopsy (SLB)—diagnostic, not therapeutic
   Procedure: video-assisted thoracoscopic sampling of lung tissue. Why: when high-resolution CT and multidisciplinary review cannot confirm the diagnosis. Notes: carries risk; many patients today are diagnosed without SLB using guideline algorithms.

---

Prevention and risk-reduction tips

1. No smoking; avoid secondhand smoke.

2. Reduce dust, molds, and fumes at home/work; use ventilation and masks.

3. Keep vaccines up to date (flu, COVID-19, pneumococcal, RSV where eligible).

4. Treat GERD and avoid late meals to limit aspiration.

5. Practice hand hygiene and avoid sick contacts during surges.

6. Maintain regular, moderate exercise within your plan.

7. Sleep well; test and treat sleep apnea if suspected.

8. Review medicines with your clinician to avoid lung-toxic drugs when possible.

9. Use oxygen exactly as prescribed; don’t ration it.

10. Seek early care for fevers, new sputum, or sudden breathlessness.

---

When to see a doctor urgently

• Sudden increase in breathlessness or oxygen needs, especially over hours to days.

• New chest pain, blue lips, severe dizziness, or fainting.

• Fever, chills, or new colored sputum suggesting infection.

• Coughing up blood.

• Oxygen saturation repeatedly below your target despite oxygen use.

• Rapid weight loss, swelling of legs, or signs of right-heart strain.

• Any medication side effect that is persistent or severe (e.g., intense diarrhea on nintedanib, sun-rash on pirfenidone, jaundice, dark urine).

---

What to eat and what to avoid

1. Prioritize protein (fish, eggs, poultry, legumes, dairy/soy) to maintain muscle for rehab.

2. Colorful fruits and vegetables daily for antioxidants and fiber.

3. Whole grains for steady energy.

4. Healthy fats (olive oil, nuts, seeds) to meet calories without large meal volumes.

5. Small, frequent meals if breathlessness limits large meals.

6. Limit reflux triggers: large late dinners, alcohol, mint, chocolate, spicy/fatty foods.

7. Hydrate to keep mucus thin unless on fluid restriction.

8. Sun protection if on pirfenidone and maintain adequate vitamin D intake.

9. Moderate sodium if you have swelling or pulmonary hypertension/right-heart strain.

10. Avoid unregulated “cure” supplements and high-dose antioxidants without clinician input.

---

Frequently asked questions (FAQs)

1) Is IPF the same as COPD or asthma?
No. COPD and asthma affect airways and are mainly obstructive. IPF scars the lung tissue itself (restrictive). Treatments differ.

2) What causes IPF?
We don’t fully know. Aging, genetics (telomere and surfactant genes), prior smoking, and inhaled exposures may contribute. The result is abnormal healing after tiny lung injuries.

3) Can IPF be cured?
There is no medicine that removes scarring. Lung transplant can replace diseased lungs in selected people.

4) Do antifibrotic drugs really help?
Yes. Nintedanib and pirfenidone slow the rate of lung function decline. They don’t reverse fibrosis but can preserve function longer.

5) Can I take both antifibrotics together?
Combination therapy is an area of study. Most people use one agent; switching or dose-adjusting is common if side effects occur. Follow your specialist’s advice.

6) How will I know if treatment works?
Your team tracks symptoms, walking tests, oxygen needs, and lung function (FVC). Slower decline is a success.

7) Will I need oxygen forever?
Some people need oxygen only during activity or sleep at first. Over time, many need more. Using oxygen as prescribed protects your heart and brain—don’t fear it.

8) What exercise is safe?
Moderate, supervised exercise from pulmonary rehab is safe and helpful. Use the “talk test,” your pulse-ox targets, and your therapist’s plan.

9) Should I move to a different climate?
There’s no perfect climate. Very cold, dry, or smoky air can worsen cough. Practical controls (humidification, masks, air filters) matter more than geography.

10) Is cough a sign things are getting worse?
Cough often persists due to airway sensitivity and reflux. Worsening cough with breathlessness, fever, or desaturation should prompt medical review.

11) Do reflux medicines help IPF itself?
Treating clear GERD helps symptoms and may reduce micro-aspiration. Whether it slows IPF is uncertain; use when GERD is present.

12) Are stem cells a cure?
No approved stem-cell cure exists for IPF. Avoid commercial clinics. Consider only regulated clinical trials.

13) Can vaccines make me sick?
Inactivated and recombinant vaccines cannot cause the infections they prevent. Side effects are usually mild and short-lived. They are strongly recommended unless contraindicated.

14) What about travel and flights?
Plan ahead. Airlines have oxygen rules. Bring a letter, extra batteries, and medications. At altitude, you may need higher oxygen flow—test beforehand if possible.

15) How can my family help?
Join education sessions, learn the action plan, help with pacing and home safety, and encourage rehab and vaccinations. Emotional support matters greatly.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 06, 2025.

PDF Documents For This Disease Condition References